Q-omics provides the consensus-scored ZNF852 profile across patient tissues and cancer cell-line models. ZNF852 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ZNF852 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZNF852 RNA expression shows 21,109 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight READ, THCA, and KIRP as cancer lineages where ZNF852 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF852 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF852 survival associations across molecular data types. ZNF852 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF852 RNA expression–survival associations across cancer types. High ZNF852 expression shows unfavorable associations in THCA, but favorable associations in READ, HNSC, KIRC, BRCA and UCS. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for ZNF852 RNA expression.
This table summarizes ZNF852 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF852. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF852 shows lower tumor expression in THCA, KIRC and LUSC and higher tumor expression in LIHC, COAD and CHOL. The THCA box plot shows higher ZNF852 RNA expression in normal versus tumor tissue (log2 FC = −0.620, t-test p < 0.001).
This table shows molecular features associated with ZNF852 in patient tissues and cancer cell lines. In patient samples, ZNF852 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF852 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
